These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23425156)

  • 1. The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
    Lorthiois E; Breitenstein W; Cumin F; Ehrhardt C; Francotte E; Jacoby E; Ostermann N; Sellner H; Kosaka T; Webb RL; Rigel DF; Hassiepen U; Richert P; Wagner T; Maibaum J
    J Med Chem; 2013 Mar; 56(6):2207-17. PubMed ID: 23425156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
    Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
    J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
    Lorthiois E; Cumin F; Ehrhardt C; Kosaka T; Sellner H; Ostermann N; Francotte E; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1782-1786. PubMed ID: 25782742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
    Sellner H; Cottens S; Cumin F; Ehrhardt C; Kosaka T; Lorthiois E; Ostermann N; Webb RL; Rigel DF; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1787-1791. PubMed ID: 25754490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
    Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
    Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
    Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
    Göschke R; Stutz S; Rasetti V; Cohen NC; Rahuel J; Rigollier P; Baum HP; Forgiarini P; Schnell CR; Wagner T; Gruetter MG; Fuhrer W; Schilling W; Cumin F; Wood JM; Maibaum J
    J Med Chem; 2007 Oct; 50(20):4818-31. PubMed ID: 17824679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
    Iserloh U; Wu Y; Cumming JN; Pan J; Wang LY; Stamford AW; Kennedy ME; Kuvelkar R; Chen X; Parker EM; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):414-7. PubMed ID: 18023580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray structures of five renin inhibitors bound to saccharopepsin: exploration of active-site specificity.
    Cronin NB; Badasso MO; J Tickle I; Dreyer T; Hoover DJ; Rosati RL; Humblet CC; Lunney EA; Cooper JB
    J Mol Biol; 2000 Nov; 303(5):745-60. PubMed ID: 11061973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
    Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Fujimoto T; Sugita C; Miyazaki S; Tamaki K; Nagayama T; Nagai Y; Inoue S; Chiba K; Nishi T
    Bioorg Med Chem; 2013 Sep; 21(18):5907-22. PubMed ID: 23886807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of inhibitors of human renin with high oral bioavailability.
    Hoover DJ; Lefker BA; Rosati RL; Wester RT; Kleinman EF; Bindra JS; Holt WF; Murphy WR; Mangiapane ML; Hockel GM
    Adv Exp Med Biol; 1995; 362():167-80. PubMed ID: 8540316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.
    Kuhnert M; Blum A; Steuber H; Diederich WE
    J Med Chem; 2015 Jun; 58(11):4845-50. PubMed ID: 26000468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.
    Van Huis CA; Casimiro-Garcia A; Bigge CF; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Leadley RJ; Narasimhan LS; McClanahan T; Mochalkin I; Pamment M; Peterson JT; Sahasrabudhe V; Schaum RP; Edmunds JJ
    Bioorg Med Chem; 2009 Mar; 17(6):2501-11. PubMed ID: 19231206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.
    Sun X; Wen X; Chen YY; Shi C; Gao C; Wu Y; Wang LJ; Yang XH; Sun H
    Eur J Med Chem; 2015 Oct; 103():269-88. PubMed ID: 26363506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.